Skip to main content

Bone 3D

ApplicationParis, FranceFounded 2018· One of 381 Application companies tracked by AMPulse

Bone 3D provides on-demand, patient-specific 3D printed medical devices, including anatomical models for surgical planning, realistic simulators for training, and custom surgical guides.

CEO / Founder
Jérémy Adam
Team Size
51-200
Stage
Active
Total Funding
$18.9M
Latest Round
Venture Round
Key Investors
Bpifrance, The Mulliez family, Karot Capital, Caisse d'Epargne, BNP Paribas

Technology & Products

Key Products

["Patient-specific anatomical models for surgical planning","Realistic surgical simulators for training (e.g., neurosurgery, podiatry)","Custom surgical guides, splints, and implants","On-site 3D printing hubs and services integrated within hospitals"]

Technological Advantage

The company combines deep expertise in biomechanics and additive manufacturing with strong clinical partnerships. This allows for the co-development of validated, CE-marked medical devices that are precisely tailored to surgical needs, moving beyond generic printing services to offer a complete, integrated solution.

Differentiation

Value Proposition

To enhance surgical precision and improve patient outcomes by providing surgeons with on-demand, patient-specific 3D printed tools and offering realistic, accessible training solutions.

How They Differentiate

Bone 3D differentiates itself by establishing on-site 3D printing hubs within hospitals, enabling faster turnaround times and deeper collaboration with surgeons. This contrasts with competitors who typically operate on a centralized, mail-order model. Their focus is on being a complete, integrated service partner rather than just a device provider.

Market & Competition

Target Customers

Hospitals, surgeons, and medical professionals, particularly in maxillofacial surgery, neurosurgery, and orthopedics.

Industry Verticals

["Medical","Healthcare"]

Competitors

Biomodex, Materialise

Growth & Milestones

Growth Metrics

Secured a €15M funding round in 2023 to accelerate international expansion and R&D. Has grown its team significantly and expanded its hospital partnerships across France.

Major Milestones

["2018: Company founded.","2020: Raised first seed round of €1.4M.","2022: Signed a landmark contract with AP-HP to deploy 3D printing facilities across its hospital network.","2023: Secured a €15M venture funding round to fuel international growth."]

Notable Customers

AP-HP (Paris Public Hospitals), the largest hospital system in Europe; Hospices Civils de Lyon

https://www.bone3d.com

Why this company matters

Bone 3D differentiates itself from centralized medical 3D printing services by embedding its production capacity directly within hospital workflows. Founded in 2018 and headquartered in Paris, the company operates on-site additive manufacturing hubs that enable rapid, collaborative development of patient-specific devices. This in-house model contrasts with the mail-order approach of competitors like Materialise and Biomodex, allowing surgeons and engineers to iterate designs in real time.

The company's core offering spans anatomical models for surgical planning, custom guides and splints, and realistic simulators for training in specialties such as neurosurgery and podiatry. All devices are produced using polymer additive manufacturing and are CE-marked, reflecting co-development with clinical teams. Bone 3D's technological edge lies in its proprietary design processes and material applications, validated through deep partnerships with hospital systems.

Bone 3D's primary customer base includes hospitals and surgeons in maxillofacial surgery, neurosurgery, and orthopedics. Notable partners include AP-HP, the largest hospital system in Europe, and Hospices Civils de Lyon. The company has raised approximately $18.9 million from investors including Bpifrance and BNP Paribas, with a €15 million round in 2023 earmarked for European expansion and R&D.

A key strategic question is whether Bone 3D's hospital-integrated model can scale beyond France while maintaining the close collaboration that defines its value proposition. The company's growth will depend on replicating its on-site hub model across different regulatory environments and hospital procurement systems, as well as defending its niche against larger centralized competitors that may attempt to offer faster turnaround times.